COLUMBIA, Md., March 9, 2021 /PRNewswire/ -- Advarra, the
market leader in regulatory review solutions, research quality and
compliance consulting services and clinical site-centric
technologies, today announced that it has acquired Bio-Optronics,
maker of CCTrialSuite - which includes Clinical Conductor, the
leading clinical trial management system (CTMS) for health systems
and research sites, and an integrated suite of eClinical solutions.
The acquisition, in combination with Advarra's existing suite
of products and services, establishes Advarra as the site
technology market leader with extensive reach, customer loyalty and
the highest standards of customer support to the 50,000
investigators whose sites run on Advarra software.
Acquisition solidifies Advarra as the leading global technology
provider for clinical research sites.
With the acquisition of Bio-Optronics, Advarra builds on its
established relationships with academic medical centers, cancer
centers and sites through its OnCore CTMS to now include a broader
coverage of site networks and health systems of any size as well as
commercial sites supported by CCTrialSuite. Additionally, the
acquisition enhances Advarra's deep commitment to clinical research
and furthers Advarra's objective to connect the clinical trial
ecosystem – sponsors, clinical research organizations (CROs) and
sites – to make clinical research safer, smarter, and faster.
Clinical trial sites can range from research centers, academic
medical centers to hospitals and health systems, private practices,
and broader site networks. Regardless of type, sites rely on
clinical trial management technology to improve the efficiency and
effectiveness of clinical research, improve trial recruitment,
protocol adherence, financial management and compliance and to
provide greater visibility for sponsoring organizations, CROs, and
regulatory bodies.
"The addition of CCTrialSuite and Bio-Optronics' global customer
base enhances Advarra's technology portfolio and further solidifies
our position as the de-facto standard for clinical research site
technology," stated Advarra's CEO, Gadi Saarony.
"Additionally, the acquisition further strengthens our ability to
enable sites with technology and services built for their unique
needs and connect them to CROs and sponsor organizations in the
clinical trial ecosystem to accelerate the advancement of human
health."
"We're delighted to be joining Advarra, a company that shares
our purpose and values and has complementary products and
expertise," said Dan Kerpelman, CEO
of Bio-Optronics. "We look forward to leveraging our combined
strengths and broadened customer base to provide connected clinical
research and healthcare technology solutions."
The acquisition also extends Advarra's therapeutic area coverage
across oncology, cardiovascular, central nervous system, brain,
infectious disease, endocrine, metabolic, and diabetes and further
expands Advarra's international presence outside of North
America. In addition to Clinical Conductor, the CCTrialSuite
augments Advarra's existing technology capabilities to include
video and text solutions for improved patient engagement, eConsent
for improved consenting process and eSource for improved data
accuracy and quality. Bio-Optronics' healthcare technology
solutions further complement the Advarra portfolio, bringing unique
know-how in scheduling and patient safety.
The combination of Advarra and Bio-Optronics advantages sponsors
and CROs by connecting them with a network of over 50,000
investigators using Advarra site technology and over 40,000 active
investigator sites that rely on Advarra for Institutional Review
Board (IRB) services. Advarra's integration-focused
technology approach ensures site, sponsor, and CRO systems work
seamlessly together throughout the clinical trial lifecycle from
study planning and startup to conducting and closing a study.
"This acquisition significantly enhances Bio-Optronics' already
established value as a partner for sites and site networks,"
commented Paul Evans, President and
CEO of Velocity Clinical Research, a leading research site
organization and an enterprise level user of CCTrialSuite. He
further added, "The combination of Advarra and Bio-Optronics
delivers increased scale, valuable resources, and improved access
and opportunity to connect and collaborate with sponsors and
CROs."
About Advarra
Advarra advances the way clinical research is conducted:
bringing life sciences companies, CROs, research sites,
investigators, and academia together at the intersection of safety,
technology, and collaboration. With trusted IRB and IBC review
solutions, innovative technologies, experienced consultants, and
deep-seated connections across the industry, Advarra provides
integrated solutions that safeguard trial participants, empower
clinical sites, ensure compliance, and optimize research
performance. Advarra is advancing clinical trials to make them
safer, smarter, and faster. For more information, visit
www.advarra.com.
About Bio-Optronics
Bio-Optronics is a leading software and services company
dedicated to providing user-focused applications for healthcare
organizations that positively impact operational performance and
financial results. With applications focused on clinical research,
automated resource utilization and patient safety, Bio-Optronics
solutions are used by thousands of healthcare organizations
worldwide to simplify complex clinical processes, enhance financial
performance, ensure regulatory compliance, increase patient safety,
boost efficiency, and ensure the overall quality of results.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/advarra-acquires-bio-optronics-maker-of-clinical-conductor-trialsuite-301242844.html
SOURCE Advarra